Overview

Docosahexaenoic acid (DHA) is a 22-carbon omega-3 fatty acid that serves as a major structural component of the human brain, cerebral cortex, and retina. It is synthesized in small amounts from alpha-linolenic acid (ALA), but dietary intake from fatty fish such as salmon, mackerel, and sardines or from marine algae supplements is considered the primary means of maintaining adequate levels.

DHA plays a crucial role in neurodevelopment, particularly during the third trimester of pregnancy and early infancy, when it accumulates rapidly in the developing brain and eyes. Adequate maternal DHA status is associated with improved cognitive outcomes and visual acuity in infants. In adults, DHA contributes to neuroplasticity, anti-inflammatory signaling through specialized pro-resolving mediators, and maintenance of cardiovascular health by supporting healthy triglyceride levels and endothelial function.

Supplemental DHA is available from fish oil, krill oil, and algal oil sources, with algal DHA being the preferred option for vegetarians and vegans. Typical supplemental doses range from 200 to 1,000 mg per day. Major health organizations recommend regular consumption of omega-3-rich fish or equivalent supplementation, and DHA is a required addition to infant formula in many countries.

Mechanism of Action

"

Membrane Biophysics & Fluidity\n\nDocosahexaenoic acid (DHA, 22:6n-3) is a 22-carbon omega-3 polyunsaturated fatty acid with six cis double bonds that create a uniquely flexible and space-filling conformation. DHA is preferentially incorporated into phosphatidylethanolamine (PE) and phosphatidylserine (PS) at the sn-2 position of neuronal and retinal membrane phospholipids, where it modulates membrane fluidity, curvature, and the formation of lipid raft microdomains critical for receptor clustering and signal transduction (PMID: 19022225).\n\n

Specialized Pro-Resolving Mediators (SPMs)\n\nDHA is the precursor for resolvins (RvD1-RvD6), protectins (PD1/neuroprotectin D1), and maresins (MaR1, MaR2), synthesized via sequential 15-lipoxygenase and 5-lipoxygenase enzymatic oxidation. These SPMs actively resolve inflammation by inhibiting neutrophil infiltration, enhancing macrophage phagocytosis of apoptotic cells (efferocytosis), and suppressing NF-kB-driven cytokine production without immunosuppression (PMID: 24675092).\n\n

Neuroprotective Signaling\n\nNeuroprotectin D1 (NPD1), synthesized from DHA by 15-LOX in neurons, activates anti-apoptotic gene expression (Bcl-2, Bcl-xL) while suppressing pro-apoptotic caspase-3 and Bax. NPD1 also inhibits COX-2 and TNF-a expression in glial cells, reducing neuroinflammation. DHA itself enhances BDNF expression via CREB activation and supports synaptic plasticity through effects on synapsin and glutamate receptor trafficking (PMID: 15672175).\n\n

Retinal Photoreceptor Function\n\nDHA constitutes over 50% of total fatty acids in photoreceptor outer segment disk membranes, where its unique conformational flexibility facilitates rhodopsin conformational changes during phototransduction and supports rapid G-protein signaling kinetics."

Reconstitution Calculator

Research

Safety Profile

Safety Profile: DHA (Docosahexaenoic Acid)

Overview DHA is an omega-3 long-chain polyunsaturated fatty acid essential for brain development, retinal function, and cardiovascular health. Found naturally in fatty fish, algae, and breast milk, DHA supplementation has an excellent safety profile supported by extensive clinical research. The FDA has granted GRAS (Generally Recognized as Safe) status to DHA from multiple sources.

Common Side Effects

• Fishy aftertaste, belching, and halitosis (most common complaint with fish oil-derived DHA)
• Mild gastrointestinal symptoms: nausea, bloating, diarrhea, and indigestion
• Loose stools, particularly at higher doses
• Mild body odor changes
• Occasional nosebleeds due to mild antiplatelet effects

Serious Adverse Effects

• Increased bleeding time at high doses (>3 g/day combined EPA/DHA), though clinically significant bleeding is rare
• Potential for increased LDL cholesterol levels with DHA supplementation (typically 5-10%), distinct from EPA which tends to be LDL-neutral
• Atrial fibrillation: recent large trials (STRENGTH, OMEMI) suggest high-dose omega-3s (particularly >2 g/day) may slightly increase AF risk in susceptible individuals
• Potential for lipid peroxidation with poor-quality or oxidized supplements
• Hypervitaminosis A and D risk with cod liver oil-derived products (not with purified DHA)

Contraindications

• Known allergy to fish or shellfish (for fish-derived DHA; algal DHA is an alternative)
• Active bleeding or hemorrhagic stroke
• Scheduled surgery within 1-2 weeks (consider discontinuation due to antiplatelet effects, though many surgeons now consider this unnecessary)
• Known hypersensitivity to DHA supplements or excipients

Drug Interactions

• Anticoagulants and antiplatelet agents (warfarin, aspirin, clopidogrel): additive bleeding risk at high doses; INR monitoring advised with warfarin
• Antihypertensive medications: DHA may have mild blood pressure-lowering effects (2-4 mmHg), potentially additive
• Statins: generally safe and commonly co-prescribed; DHA may slightly increase LDL while reducing triglycerides
• Orlistat and other fat absorption inhibitors: may reduce DHA absorption
• Cyclosporine: omega-3s may enhance immunosuppressive effects

Special Populations

• Pregnancy and breastfeeding: DHA supplementation (200-300 mg/day) is recommended for fetal brain and retinal development
• Infants: DHA is a standard addition to infant formula; well-established safety
• Elderly: well-tolerated; cardiovascular and cognitive benefits may outweigh minimal risks

Dosage Considerations

• General health: 200-500 mg DHA/day
• Combined EPA+DHA should not exceed 3 g/day per FDA guidance from supplements
• Algal DHA is a suitable vegetarian/vegan alternative with equivalent safety

Pharmacokinetic Profile